Afzelius Lovisa, Zamora Ismael, Masimirembwa Collen M, Karlén Anders, Andersson Tommy B, Mecucci Silvio, Baroni Massimo, Cruciani Gabriele
DMPK and Bioanalytical Chemistry, AstraZeneca R&D, S-431 83 Mölndal, Sweden.
J Med Chem. 2004 Feb 12;47(4):907-14. doi: 10.1021/jm030972s.
A conformer- and alignment-independent three-dimensional structure-activity relationship (3D-QSAR) model has been derived that is based on flexible molecular interaction fields calculated in GRID and the subsequent description of these fields by use of alignment-independent descriptors derived in ALMOND. The training set consisted of 22 diverse and flexible competitive inhibitors of the drug-metabolizing enzyme CYP2C9 and generated a model with r(2) of 0.81 and q(2) of 0.62. The predicitive capacity of the model was externally evaluated with a test set of 12 competitive inhibitors and 11 out of 12 were predicted within 0.5 log unit. The most relevant points of interaction in the model correlated well to the amino acids involved in CYP2C9-substrate/inhibitor binding in the active site of a CYP2C9 homology model, further validating the mechanistic sense of our model. This approach offers the possibility to derive predicitve 3D-QSAR models without the need for an alignment rule for chemically diverse ligands and in the absence of target protein crystal structure information.
已推导得到一种与构象和比对无关的三维结构-活性关系(3D-QSAR)模型,该模型基于在GRID中计算的柔性分子相互作用场,以及随后通过使用在ALMOND中推导的与比对无关的描述符对这些场进行的描述。训练集由22种不同的、柔性的药物代谢酶CYP2C9竞争性抑制剂组成,生成的模型r(2)为0.81,q(2)为0.62。该模型的预测能力通过一组12种竞争性抑制剂的测试集进行了外部评估,12种中有11种的预测误差在0.5对数单位以内。模型中最相关的相互作用点与CYP2C9同源模型活性位点中CYP2C9-底物/抑制剂结合所涉及的氨基酸高度相关,进一步验证了我们模型的机理合理性。这种方法提供了在无需对化学结构多样的配体进行比对规则且缺乏靶蛋白晶体结构信息的情况下推导预测性3D-QSAR模型的可能性。